<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462500</url>
  </required_header>
  <id_info>
    <org_study_id>2229-519-28930</org_study_id>
    <nct_id>NCT01462500</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Miltefosine in Children and Adults</brief_title>
  <acronym>PK</acronym>
  <official_title>Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Internacional de Entrenamiento e Investigaciones Médicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Internacional de Entrenamiento e Investigaciones Médicas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics of miltefosine in children and
      adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the
      parasitologic response. The results will provide pharmacologic bases to optimize the use of
      miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base
      to assess the impact of pharmacokinetic behavior in children and adults on the emergence of
      drug resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label phase IV clinical trial of miltefosine, designed to evaluate intracellular and
      plasma drug pharmacokinetics in children and adults using a population pharmacokinetics
      design. Two study groups have been defined: 1) children 2-12 years of age (n=30) and 2)
      adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous
      leishmaniasis. The participants will receive supervised standard treatment with miltefosine:
      1.8 - 2.5 mg/Kg of weight for 28 days.

      Miltefosine concentration will be determined in plasma and Peripheral Blood Mononuclear Cell
      (PBMCs), from 3 or 10ml peripheral blood samples in children and adults respectively.
      Sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months
      1, 2, 3 and 6 post-treatment.

      A population pharmacokinetics analysis will be performed using a non-linear model of mixed
      effects with the software Nonlinear Mixed-effects Model (NONMEM), R and Piranha. Parasite
      burden will be determined by 7SLRNA Quantitative Polymerase Chain Reaction (qPCR) of
      Leishmania from swab samples of lesions and extralesional tissues before and at the end of
      treatment. The relationship between pharmacokinetics and parasite persistence/burden will be
      determined by correlation analysis and pharmacodynamic modeling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracellular and plasma concentration of miltefosine</measure>
    <time_frame>Participants will be followed up to 26 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parasite burden in lesions and extralesional tissues.</measure>
    <time_frame>Participants will be followed up to 26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Miltefosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine</intervention_name>
    <description>Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.</description>
    <arm_group_label>Miltefosine</arm_group_label>
    <other_name>pharmacokinetic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 2-12 years of age, or 18-60 years of age

          -  Weight greater than 10 kg

          -  Parasitologic confirmation of cutaneous leishmaniasis

          -  Normal hepatic and kidney function

        Exclusion Criteria:

          -  Pregnant or lactating women, and women who are planning to conceive during the study
             or that reject the use of birth control methods.

          -  Use of drugs with antileishmanial potential during the previous 6 months, including
             pentavalent antimonials, amphotericin B, miltefosine, and pentamidine

          -  Mucocutaneous or visceral leishmaniasis

          -  For female children, menses or other evidence of reproductive maturity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy C Saravia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas</name>
      <address>
        <city>Cali</city>
        <state>Valle</state>
        <zip>5930</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20. Epub 2006 May 26. Review.</citation>
    <PMID>16730362</PMID>
  </reference>
  <reference>
    <citation>Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother. 2008 Aug;52(8):2855-60. doi: 10.1128/AAC.00014-08. Epub 2008 Jun 2.</citation>
    <PMID>18519729</PMID>
  </reference>
  <reference>
    <citation>Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006 Nov;165(11):741-6. Epub 2006 Jun 29. Review.</citation>
    <PMID>16807730</PMID>
  </reference>
  <reference>
    <citation>Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209. Review.</citation>
    <PMID>18721114</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Miltefosine</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>cutaneous leishmaniasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

